Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Trane Technologies | Meta Platforms | Eli Lilly and Company | |
|---|---|---|---|
| Moat rating | narrow Trane's FY2025 Form 10-K (filed 5 February 2026) makes exactly one rank claim about itself and it is hedged: 'We are one of the leading manufacturers in the world of HVAC systems and services and transport temperature control products and services'. It sits inside a Competitive Conditions section that opens 'Our products and services are sold in highly competitive markets throughout the world', describes 'a wide variety of competitors that vary by product line and services' including 'well-established regional or specialized competitors, as well as larger U.S. and non-U.S. corporations or divisions of larger companies', and names price first among 'the principal methods of competition in these markets', ahead of quality, delivery, service and support, technology and innovation. The risk factors push the same way: 'The markets that we serve are highly competitive', 'consolidation and new entrants (including non-traditional competitors) within our industries' 'could result in increased competition and pricing pressures', Trane competes 'with large companies and with smaller, local operators who may have customer, regulatory or economic advantages in the geographies in which they are located', and 'some of our competitors may employ pricing and other strategies that are not traditional'. What the filing does evidence is an advantage that gets paid for: 2025 net revenues of $21,321.9 million, up 7.5% from $19,838.2 million, of which the company's own bridge assigns 3.0 points to pricing; gross margin up 50 basis points to 36.2%; operating income of $3,967.4 million, 18.6% of revenues; and firm backlog up to $7,769.4 million from $6,747.7 million. But that advantage is not uniform in the same document: the EMEA pricing component was (0.3)% and its segment adjusted EBITDA margin fell 150 basis points to 18.3%, and Asia Pacific organic revenue fell 2.5% on 'lower volumes in China'. A position the company itself will only call 'one of the leading', defended in markets it calls highly competitive and priced unevenly across its three segments, is protection that is real but bounded. | narrow The FY2025 10-K shows a real moat — 3.58 billion Family daily active people (December 2025 average, +7% YoY) and a 52% Family of Apps operating margin — but the same filing qualifies its durability on three fronts it discloses itself: it says "We face significant competition in every aspect of our business"; it names "competitive products and services, such as TikTok, that have reduced some users' engagement with our products and services"; and it discloses that since 2020 it has been "subject to a lawsuit by the FTC alleging that we violated antitrust laws" that "seeks ... divestiture or reconstruction of Instagram and WhatsApp." A moat a regulator is actively litigating to break up, and whose ad targeting depends on iOS/Android policies Meta does not set, reads narrow rather than wide. | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. |
| Moat type | switching costs The filing rules out the obvious alternative in its own words. Item 1's Patents and Licenses paragraph says the Company 'does not consider any single patent, trademark, copyright, trade secret, proprietary technology, technical data, business process or any other confidential information (or any related group of any such items) to be of material importance to any segment or to the business as a whole', and the matching risk factor is blunter: 'we do not believe that our business is materially dependent on a single intellectual property right or any group of them. In our opinion, engineering, production skills and experience are more responsible for our market position than our patents and/or licenses.' That is a company disclaiming an IP moat. Where the 10-K does locate durability is the installed equipment and the channel wrapped around it. The overview frames the entire growth plan that way - 'As an industry leader with an extensive global install base, our growth strategy includes expanding recurring revenue through services and rental options' - the principal products and services table carries 'Service agreements', 'Repair and maintenance services', 'Parts and supplies (aftermarket and OEM)' and 'Rental services' alongside the equipment itself, the Distribution paragraph puts U.S. sales through Trane's own 'branch sales offices, distributors and dealers across the country' and non-U.S. sales through 'numerous subsidiary sales and service companies with a supporting chain of distributors throughout the world', and the accounting policy confirms the contracts are multi-period: 'For extended warranties and long-term service agreements, revenue for these distinct performance obligations are recognized over time on a straight-line basis over the respective contract term.' Long-lived equipment serviced under term agreements by the manufacturer's own branches is the asset this filing keeps pointing at, which is why the moat is read as an installed-base tie rather than a patent estate. | network effects The 10-K Competition section describes a three-sided network in Meta's own words: it competes "to attract, engage, and retain people who use our products, to attract and retain businesses that use our free or paid business and advertising services, and to attract and retain developers who build compelling applications that integrate with our products," and elsewhere cites "the scale of our user, advertiser, and developer base." The same filing rules out an IP-based moat: "We do not believe that our proprietary technology is dependent on any single patent or copyright or groups of related patents or copyrights." | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. |
| Leadership | co leader The company's own claim is comparative but never exclusive: 'We are one of the leading manufacturers in the world of HVAC systems and services and transport temperature control products and services' - one of, with no rank, no share figure and no competitor named anywhere in the filing. Competitive Conditions sets that against 'well-established regional or specialized competitors, as well as larger U.S. and non-U.S. corporations or divisions of larger companies', and the risk factors add that Trane competes 'with large companies and with smaller, local operators who may have customer, regulatory or economic advantages in the geographies in which they are located'. The scale behind the claim is substantial and disclosed - $21,321.9 million of 2025 net revenues, products sold in approximately 100 countries, backlog of $7,769.4 million - but the 10-K never asserts the top position in any market it serves. | co leader Top-tier but shared: the 10-K reports 3.58 billion Family daily active people and $196.18 billion of 2025 advertising revenue, yet also states that TikTok has "reduced some users' engagement," that "each of Apple and Google have integrated competitive products with iOS and Android," and that Meta competes "with companies in the development and application of AI, particularly with respect to the development of frontier AI models." | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. |
| Pricing power | moderate Price is a separately disclosed component of growth in this filing and it is positive: of the 7.5% increase in 2025 net revenues, the company's bridge assigns 3.0% to pricing against 3.2% volume, 0.8% acquisitions and 0.5% currency, and gross margin rose 50 basis points to 36.2% 'primarily due to gross productivity and price realization, partially offset by inflation'. In the Americas the price component was 3.8% of an 8.0% revenue increase, and that segment's adjusted EBITDA margin rose 70 basis points to 21.6% 'primarily due to price realization and gross productivity, partially offset by inflation and continued business reinvestment'. What holds the band below strong is in the same bridge and the same risk factors: EMEA pricing was (0.3)% and its segment margin fell 150 basis points to 18.3%; Asia Pacific pricing was 0.4% on organic revenue down 2.5%; consolidation and new entrants 'could result in increased competition and pricing pressures'; and 'in the event there is deflation, we may experience pressure from our customers to reduce prices.' Price that sticks in the Americas, disappears in EMEA and is disclaimed as durable in the risk factors is moderate rather than strong. | strong Ad-auction pricing, not list prices: the 10-K reports "the average price per ad increased by 9%" in 2025 after "an increase of 10% in 2024," driven by "an increase in advertising demand," alongside worldwide ARPP of $57.03 (+15%) and a 52% Family of Apps operating margin. The filing notes the gain was "partially offset by a higher number of ad impressions delivered ... in products, such as Reels, that monetize at lower rates." | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. |
| Summary | Trane Technologies is the Trane and Thermo King equipment maker - the FY2025 10-K opens by calling it 'a global climate innovator' selling HVAC, transport refrigeration and custom refrigeration through 'our strategic brands, Trane® and Thermo King®' - organised in three regional segments that produced 2025 net revenues of $17,168.8 million (Americas), $2,802.1 million (EMEA) and $1,351.0 million (Asia Pacific), with 'Approximately 25% of our net revenues in 2025 ... derived outside the U.S.' across 'approximately 100 countries' and 'no single external customer that accounted for more than 10% of our consolidated net revenues in 2025, 2024 or 2023'. The filing is candid that the markets are contested and equally candid that its position does not rest on intellectual property: 'engineering, production skills and experience are more responsible for our market position than our patents and/or licenses.' The durable asset it does describe is the installed base and the aftermarket attached to it - an 'extensive global install base' whose monetisation through 'services and rental options' is the stated growth strategy, reached through branch sales offices, dealers and distributors, with service agreements, repair and maintenance, aftermarket and OEM parts and rental all listed among the principal products. The 2025 financials carry that signature: revenues up 7.5% to $21,321.9 million split 3.2 points volume, 3.0 points price, 0.8 points acquisitions and 0.5 points currency; gross margin up 50 basis points to 36.2% 'primarily due to gross productivity and price realization, partially offset by inflation'; and backlog of $7,769.4 million on equipment where 'orders for specialized equipment or specific customer applications are submitted with extended lead times'. The limits are in the same filing. Price contributed 3.8% in the Americas but (0.3)% in EMEA and 0.4% in Asia Pacific; EMEA's segment adjusted EBITDA margin fell 150 basis points to 18.3%; Asia Pacific organic revenue fell 2.5% on 'lower volumes in China'; the Americas' otherwise strong year was 'partially offset by weaker volume in our Residential business'; and the risk factors warn that refrigerant regulation 'could make some of our existing HVAC and refrigeration products non-compliant or obsolete', with the company 'developing and selling our next generation products that utilize lower global warming potential solutions' against $347.6 million of 2025 research and development spending. For the AI build-out specifically, the link exists in the filing but is unsized: 'Data center HVAC systems', 'Data center liquid cooling solutions', 'Data center facility controls' and 'Data center services' appear in the principal products and services table, and those four entries are the only places the phrase occurs anywhere in the 10-K - no revenue, no ranking, no share, and no mention at all in the MD&A discussion of 2025 growth. | Meta's advantage is the size of the user-advertiser-developer network it monetizes, not proprietary technology: 3.58 billion daily active people across the Family of Apps produced $196.18 billion of 2025 advertising revenue at a 52% segment operating margin, and the 10-K attributes 2025's 9% rise in average price per ad to "an increase in advertising demand, which we believe is mostly due to ongoing improvements to our ad performance from our ad targeting and measurement tools." The filing is equally explicit about what limits that network: TikTok has "reduced some users' engagement," Apple's iOS changes "limit our ability ... to target and measure ads effectively," the April 2025 European Commission decision against its "subscription for no ads" model pushed EU users onto less personalized ads that are "less relevant and effective," and the FTC is seeking divestiture of Instagram and WhatsApp. Reality Labs, the intended next platform, lost $19.19 billion in 2025 on $2.21 billion of revenue and is expected "to continue to operate at a loss for the foreseeable future." | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." |
| Chain position | Trane sits on the facility side of the AI build-out rather than in the compute stack. Its FY2025 10-K lists 'Data center HVAC systems', 'Data center liquid cooling solutions', 'Data center facility controls' and 'Data center services' among its principal products and services, alongside 'Thermal energy storage' and 'Smart and AI-enabled services'. Those four entries are the only occurrences of the phrase in the entire filing: there is no data center revenue figure, no ranking, no named competitor and no separate reporting - segment disclosure stops at Americas, EMEA and Asia Pacific, and the MD&A attributes the Americas' 7.4% organic growth to 'realization of price increases and higher volumes led by strong demand within our Commercial HVAC business' without naming an end market. | Demand-side anchor of the AI build-out: the 10-K reports $72.22 billion of 2025 capital expenditures and says Meta has "designed and built our own data centers and key portions of our technical infrastructure," funded entirely by the advertising business. | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.13 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.17 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. |